MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS), which is responsible for 50% of life-threatening infections in new-born.
If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact firstname.lastname@example.org or +45 5150 0560
Copyright 2013 Danskbiotek. All rights reserved.
created by: Mastafu Design